Table 1. Patient characteristics, laboratory values and medical treatment.
| Pediatric patients | Adult patients | ||||
| De novo | Previously diagnosed | De novo | Previously diagnosed | ||
| Demographics | |||||
| Patients (n) | 15 | 15 | 15 | 15 | |
| Sex (n) | |||||
| Male | 6 | 5 | 7 | 6 | |
| Female | 9 | 10 | 8 | 9 | |
| Median age (IQR) | 13 (9-15) | 15 (11-16) | 29 (25-40) | 31 (25-39) | |
| Disease parameters | |||||
| Phenotype (n) | |||||
| Remission | - | 3 | - | 2 | |
| Proctitis | 5 | 4 | 6 | 2 | |
| Left sided | 1 | 3 | 4 | 2 | |
| Extensive | 9 | 5 | 5 | 9 | |
| UCEIS (median (IQR)) | 3 (1-6) | 1 (0-4) | 3 (1-5) | 1 (0-4) | |
| Geboes score (n) | |||||
| 0-1 / 2-3 / >3 | 2 / 9 / 4 | 6 / 6 / 3 | 4 / 3 / 8 | 8 / 5 / 2 | |
| Biomarkers (median [IQR]) | |||||
| Fecal calprotectin (μg/g)a | 1340 (97-1800) | 525 (62-1080) | 1800 (1130-1800) | 1042 (300-1800) | |
| C-reactive protein (mg/L) | 1 (0-9) | 1 (0-2) | 2 (0-5) | 8 (3-22) | |
| Albumin (g/L) | 37 (34-40) | 38 (36-39) | 38 (35-43) | 36 (33-40) | |
| Hemoglobin (mmol/L) | 7.5 (7.1-8.3) | 7.8 (6.9-8.1) | 8.6 (8.1-9.5) | 8.1 (7.5-8.8) | |
| Erythrocyte sedimentation rate | 10.5 (3-16) | 6 (4-18) | 5 (3-16) | 13 (3-21) | |
| Neutrophils (E^9/L) | 4 (3-6) | 4 (3-4) | 4 (4-5) | 6 (4-8) | |
| Treatment (n) | |||||
| Oral 5-aminosalicylic acid | - | 12 | 4 | 10 | |
| Topic 5-aminosalicylic acid | - | 3 | 3 | 9 | |
| Systemic corticosteroids | - | 2 | - | 2 | |
| Topical corticosteroids | - | 1 | - | 1 | |
| Thiopurines | - | 7 | - | 4 | |
| Biologics | - | 6 | - | 1 | |
Due to laboratory restrictions fecal calprotectin was capped at 1800 μg/g. IQR, Interquartile range. N, number. UCEIS, Ulcerative Colitis Endoscopic Index of Severity.